Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The impact of alarm sounds on patient sleep in the intensive care unit: A scoping review.

Journal of critical care·2026

Same author

Enhancing Early Detection of Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Integrating AI With Histopathological Assessments.

Experimental dermatology·2025

Same author

Enhanced metastatic risk stratification for cutaneous squamous cell carcinoma by combining clinical guidelines with the Erasmus MC model: Results from 2 nationwide nested case-control studies.

Journal of the American Academy of Dermatology·2025

Same author

The prognostic power of anti-topoisomerase I and anti-centromere antibodies in systemic sclerosis - A systematic review of the literature.

Seminars in arthritis and rheumatism·2025

Same author

Evolution of bone lesions in adults with chronic nonbacterial osteitis (CNO): A long-term follow-up study.

Seminars in arthritis and rheumatism·2025

Same author

Work in the picture? The reporting of and effects on work outcomes in exercise therapy trials in people with rheumatoid arthritis or axial spondyloarthritis: a systematic review.

Scandinavian journal of rheumatology·2025

Search research articles

Related Experiment Video

Updated: May 15, 2026

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Published on: January 26, 2024

Genetic variants in pre-eclampsia: a meta-analysis.

A J Buurma¹, R J Turner, J H M Driessen

¹Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. a.j.buurma@lumc.nl

Human Reproduction Update

|January 10, 2013

Summary

This summary is machine-generated.

This meta-analysis identified seven genetic variants linked to pre-eclampsia risk. Many of these genetic factors for pre-eclampsia are also associated with cardiovascular disease, indicating shared genetic underpinnings.

More Related Videos

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo

Published on: August 2, 2017

Related Experiment Videos

Last Updated: May 15, 2026

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Published on: January 26, 2024

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo

Published on: August 2, 2017

Area of Science:

Genetics
Obstetrics
Cardiovascular Medicine

Background:

Pre-eclampsia exhibits familial clustering, suggesting a genetic susceptibility component.
Numerous studies have explored genetic associations with pre-eclampsia, but replication has been inconsistent.
This meta-analysis focuses on reproducibly associated genetic variants.

Purpose of the Study:

To assess the pooled effect of genetic variants reproducibly associated with pre-eclampsia.
To identify specific genetic variants contributing to pre-eclampsia pathogenesis.
To explore shared genetic risk factors between pre-eclampsia and cardiovascular disease.

Main Methods:

Systematic literature search of PubMed, Embase, and Web of Science for gene-pre-eclampsia association studies.
Inclusion of genetic variants significantly associated in an initial study and independently reproduced.
Meta-analysis using a random-effects model to calculate pooled odds ratios at the allele level.

Main Results:

Identified 22 replicated genetic variants from 542 relevant studies.
Seven genetic variants remained significantly associated with pre-eclampsia after meta-analysis.
Associated genes include ACE, CTLA4, F2, FV, LPL, and SERPINE1.

Conclusions:

Seven genetic variants are significantly associated with pre-eclampsia.
Shared genetic risk factors exist between pre-eclampsia and cardiovascular disease.
Future research should investigate the role of these variants in pre-eclampsia development.